Skip to main content
AAN.com
Articles
January 1, 1998

Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease
Relationship to severity of dementia and apolipoprotein E genotype

January 1998 issue
50 (1) 164-168

Abstract

Patients with Alzheimer's disease (AD) have elevations of fasting plasma insulin that are hypothesized to be associated with disrupted brain insulin metabolism. We examined paired fasted plasma and CSF insulin levels in 25 patients with AD and 14 healthy age-matched adults and determined whether insulin levels were related to severity of dementia and apolipoprotein E-ϵ4 homozygosity, a known genetic risk factor for AD. The AD patients had lower CSF insulin, higher plasma insulin, and a reduced CSF-to-plasma insulin ratio when compared with healthy adults. The differences were greater for patients with more advanced AD. Patients who were not apolipoprotein E-ϵ4 homozygotes had higher plasma insulin levels and reduced CSF-to-plasma ratios, whereas ϵ4 homozygotes with AD had normal values. Both plasma and CSF insulin levels are abnormal in AD, and there are metabolic differences among apolipoprotein E genotypes.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Adamo M, Raizada, MK, LeRoith D. Insulin and insulin-like growth factor receptors in the nervous system. Mol Neurobiol 1989;3:71-100.
2.
Unger J, McNeill TH, Moxley RT III, White M, Moss A, Livingston JN. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience 1989;31:143-157.
3.
Zahniser NR, Goens MB, Hanaway PJ, Vinych JV. Characterization and regulation of insulin receptors in rat brain. J Neurochem 1984;42:1354-1362.
4.
Marks JL, King MG, Baskin DG. Localization of insulin and type 1 IGF receptors in rat brain by in vitro autoradiography and in situ hybridization. Adv Exp Med Biol 1991;293:459-470.
5.
Craft S, Newcomer J, Kanne S, et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 1996;17:123-130.
6.
Craft S, Asthana S, Newcomer J, et al. Insulin-induced enhancement of memory in Alzheimer's disease is independent of glucose[abstract]. Soc Neurosci Abstr 1996;22:1177.
7.
Park CR, Seeley RJ, Woods SC. ICV insulin increases performance on a passive avoidance task [abstract]. Soc Neurosci Abstr 1995;21:949.
8.
Messier C, Destrade C. Insulin attentuates scopolamine-induced memory deficits. Psychobiology 1994;22:16-21.
9.
Craft S, Dagogo-Jack SE, Wiethop BV, et al. The effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Beh Neurosci 1993;107:926-940.
10.
Meneilly GS, Hill A. Alterations in glucose metabolism in patients with Alzheimer's disease. J Am Geriatr Soc 1993;41:710-714.
11.
Frolich L, Blum-Degen D, Hoyer S, Riederer P. Regional distribution of insulin, insulin receptors and IGF-I receptors in post-mortem brain cortex in aging and in dementia of Alzheimer type [abstract]. Neurobiol Aging 1996;17:s184.
12.
Kamboh MI. Apolipoprotein E polymorphism and susceptibility to Alzheimer's disease. Hum Biol 1995;67:195-215.
13.
McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
14.
Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
15.
Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY. Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity. J Clin Endocrinol Metab 1995;80:1399-1406.
16.
Baura GD, Foster DM, Porte D Jr, et al. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J Clin Invest 1993;92:1824-1830.
17.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
18.
Emi M, Wu LL, Robertson MA, et al. Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics 1988;3:373-379.
19.
Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
20.
Schwartz MW, Figlewicz DP, Baskin DG, Woods SC, Porte D Jr. Insulin in the brain: a hormonal regulator of energy balance. Endocr Rev 1992;13:387-414.
21.
Jeanrenaud B. Central nervous system and peripheral abnormalities: clues to the understanding of obesity and NIDDM. Diabetologia 1994;37(suppl 2):s170-s178.
22.
Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.
23.
Squire LR. Memory and the hippocampus: a synthesis of findings with rats, monkeys, and humans. Psychol Rev 1992;99:195-231.
24.
Leloup C, Arluison M, Kassis N, et al. Discrete brain areas express the insulin-responsive glucose transporter GLUT4. Brain Res Mol Brain Res 1996;38:45-53.
25.
Simpson IA, Li K, Koehler-Stec EM, Gibbs EM, Vannucci J. Regional expression of the GLUT4 glucose transporter in mouse brain[abstract]. Soc Neurosci Abstr 1996;22:1571.
26.
Wallace WC, Akar CA, Kole HK, Egan, JM, Wolozin B. Amyloid precursor protein potentiates the neurotrophic activity of NGF through the insulin signaling pathway [abstract]. Soc Neurosci Abstr 1996;22:513.

Information & Authors

Information

Published In

Neurology®
Volume 50Number 1January 1998
Pages: 164-168
PubMed: 9443474

Publication History

Published online: January 1, 1998
Published in print: January 1998

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

Suzanne Craft, PhD
From the Geriatric Research, Education, and Clinical Centers (Drs. Craft, Peskind, and Schellenberg), Mental Health Service (Drs. Peskind and Raskind), and Department of Medicine (Drs. Schwartz and Porte), Veteran Affairs Puget Sound Health Care System, Seattle, WA; and the Departments of Psychiatry and Behavioral Sciences (Drs. Craft, Peskind, and Raskind), Medicine (Drs. Schwartz and Porte), Pharmacology (Dr. Schellenberg), and Neurology (Dr. Schellenberg), University of Washington School of Medicine, Seattle, WA.
Elaine Peskind, MD
From the Geriatric Research, Education, and Clinical Centers (Drs. Craft, Peskind, and Schellenberg), Mental Health Service (Drs. Peskind and Raskind), and Department of Medicine (Drs. Schwartz and Porte), Veteran Affairs Puget Sound Health Care System, Seattle, WA; and the Departments of Psychiatry and Behavioral Sciences (Drs. Craft, Peskind, and Raskind), Medicine (Drs. Schwartz and Porte), Pharmacology (Dr. Schellenberg), and Neurology (Dr. Schellenberg), University of Washington School of Medicine, Seattle, WA.
Michael W. Schwartz, MD
From the Geriatric Research, Education, and Clinical Centers (Drs. Craft, Peskind, and Schellenberg), Mental Health Service (Drs. Peskind and Raskind), and Department of Medicine (Drs. Schwartz and Porte), Veteran Affairs Puget Sound Health Care System, Seattle, WA; and the Departments of Psychiatry and Behavioral Sciences (Drs. Craft, Peskind, and Raskind), Medicine (Drs. Schwartz and Porte), Pharmacology (Dr. Schellenberg), and Neurology (Dr. Schellenberg), University of Washington School of Medicine, Seattle, WA.
Gerard D. Schellenberg, PhD
From the Geriatric Research, Education, and Clinical Centers (Drs. Craft, Peskind, and Schellenberg), Mental Health Service (Drs. Peskind and Raskind), and Department of Medicine (Drs. Schwartz and Porte), Veteran Affairs Puget Sound Health Care System, Seattle, WA; and the Departments of Psychiatry and Behavioral Sciences (Drs. Craft, Peskind, and Raskind), Medicine (Drs. Schwartz and Porte), Pharmacology (Dr. Schellenberg), and Neurology (Dr. Schellenberg), University of Washington School of Medicine, Seattle, WA.
Murray Raskind, MD
From the Geriatric Research, Education, and Clinical Centers (Drs. Craft, Peskind, and Schellenberg), Mental Health Service (Drs. Peskind and Raskind), and Department of Medicine (Drs. Schwartz and Porte), Veteran Affairs Puget Sound Health Care System, Seattle, WA; and the Departments of Psychiatry and Behavioral Sciences (Drs. Craft, Peskind, and Raskind), Medicine (Drs. Schwartz and Porte), Pharmacology (Dr. Schellenberg), and Neurology (Dr. Schellenberg), University of Washington School of Medicine, Seattle, WA.
Daniel Porte, Jr, MD
From the Geriatric Research, Education, and Clinical Centers (Drs. Craft, Peskind, and Schellenberg), Mental Health Service (Drs. Peskind and Raskind), and Department of Medicine (Drs. Schwartz and Porte), Veteran Affairs Puget Sound Health Care System, Seattle, WA; and the Departments of Psychiatry and Behavioral Sciences (Drs. Craft, Peskind, and Raskind), Medicine (Drs. Schwartz and Porte), Pharmacology (Dr. Schellenberg), and Neurology (Dr. Schellenberg), University of Washington School of Medicine, Seattle, WA.

Notes

Address correspondence and reprint requests to Dr. Suzanne Craft, GRECC 182B, VA Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA 98108.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Epigenetic Alterations in Alzheimer’s Disease: Impact on Insulin Signaling and Advanced Drug Delivery Systems, Biology, 13, 3, (157), (2024).https://doi.org/10.3390/biology13030157
    Crossref
  2. Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer’s Disease, Journal of Alzheimer's Disease, 101, s1, (S357-S370), (2024).https://doi.org/10.3233/JAD-240730
    Crossref
  3. Effect and Mechanism of Rapamycin on Cognitive Deficits in Animal Models of Alzheimer’s Disease: A Systematic Review and Meta-analysis of Preclinical Studies, Journal of Alzheimer's Disease, 99, 1, (53-84), (2024).https://doi.org/10.3233/JAD-231249
    Crossref
  4. AD-Like Neuropsychiatric Dysfunction in a Mice Model Induced by a Combination of High-Fat Diet and Intraperitoneal Injection of Streptozotocin, eneuro, 11, 12, (ENEURO.0310-24.2024), (2024).https://doi.org/10.1523/ENEURO.0310-24.2024
    Crossref
  5. Association among abnormal glycolipids, reproductive hormones, and cognitive dysfunction in female patients with bipolar disorder, BMC Psychiatry, 24, 1, (2024).https://doi.org/10.1186/s12888-024-05831-y
    Crossref
  6. DJ-1-mediated repression of the RNA-binding protein FMRP is predicted to impact known Alzheimer's disease-related protein networks, Journal of Alzheimer’s Disease, 102, 3, (763-777), (2024).https://doi.org/10.1177/13872877241291175
    Crossref
  7. Brain energy metabolism: A roadmap for future research, Journal of Neurochemistry, 168, 5, (910-954), (2024).https://doi.org/10.1111/jnc.16032
    Crossref
  8. Mapping the evolution of inhaled drug delivery research: Trends, collaborations, and emerging frontiers, Drug Discovery Today, 29, 2, (103864), (2024).https://doi.org/10.1016/j.drudis.2023.103864
    Crossref
  9. Non-canonical pathways associated to Amyloid beta and tau protein dyshomeostasis in Alzheimer’s disease: A narrative review, Ageing Research Reviews, 102, (102578), (2024).https://doi.org/10.1016/j.arr.2024.102578
    Crossref
  10. Emerging role of Metformin in Alzheimer’s disease: A translational view, Ageing Research Reviews, 100, (102439), (2024).https://doi.org/10.1016/j.arr.2024.102439
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share